Vortrag anllich der Fortbildungsveranstaltung Med
That same month, the journal Science declared glucagon-like peptide-1 (GLP-1) weight loss drugs its Breakthrough of the Year, beating out commendable contenders such as new malaria and Alzheimers treatments, innovative climate change research on natural carbon pumps and artificial intelligence (AI) in improving weather forecasting
One injection per week minimizes these risks
In addition to the FDAs scrutiny of outsourcing facilities and compounders in the GLP-1 space, the FDA has expressed concerns over the use of unapproved GLP-1 drugs for weight loss, 2 including dosing concerns with compounded semaglutide and tirzepatide products, salt forms that should not be used to compound semaglutide, use of retatrutide in compounding, and adverse events related to compounded versions of semaglutide and tirzepatide, among others
[1] [2] These combined actions lead to improved glycaemic control in people with type 2 diabetes and significant weight reduction